Table 4.

Outcomes comparing darifenacin or matched placebo after 12 weeks of treatment (Chapple et al 2005)

	Darifenacin(%) (7.5 mg QD)	Placebo (%)	Darifenacin(%) (15 mg QD)	Placebo (%)
Incontinence episodes/week	−8.8(−68.4)*	−7(−53.8)	−10.6(−76.8)**	7.5 (−58.3)
Incontinence episodes resulting in pad change	−4(−77.1)	−2(−47.7)	−4.8(−78.6)**	−2.7(−55.1)
Frequency of urgency/day	−2(−29)**	−1(−14.3)	−2.3(−29)**	−1.2(−16.7)
Micturition Frequency/day	−1.6(−16.6)**	−0.9(−9.1)	−1.9(−17.4)**	−1(−9.9)
Bladder capacity (mean vol void:ml)	15.4(9.6)*	7.6(4.9)	26.9(17.5)**	5.9(3.9)
Severity of urgency	−7.8(−14.2)**	−4.2(−7.8)	−9.3(−16.1)**	−4.5(−8)

Notes: Results expressed as median (%) change from baseline, at week 12;

^*p<0.01;

^**p<0.001 (Wilcoxon rank-sum test).